Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other financing activities: 2020-2025

Historic Other financing activities for Ligand Pharmaceuticals (LGND) over the last 3 years, with Sep 2025 value amounting to $14.8 million.

  • Ligand Pharmaceuticals' Other financing activities rose 6965.71% to $14.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 1095.62%. This contributed to the annual value of $426,000 for FY2024, which is 55.11% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Other financing activities stood at $14.8 million, which was up 741,800.00% from $2,000 recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Other financing activities ranged from a high of $14.8 million in Q3 2025 and a low of -$121,000 during Q1 2022.
  • Its 3-year average for Other financing activities is $2.0 million, with a median of $94,500 in 2024.
  • Examining YoY changes over the last 5 years, Ligand Pharmaceuticals' Other financing activities showed a top increase of 6,965.71% in 2025 and a maximum decrease of 96.49% in 2025.
  • Ligand Pharmaceuticals' Other financing activities (Quarterly) stood at $42,000 in 2022, then skyrocketed by 2,159.52% to $949,000 in 2023, then plummeted by 87.57% to $118,000 in 2024, then surged by 6,965.71% to $14.8 million in 2025.
  • Its last three reported values are $14.8 million in Q3 2025, $2,000 for Q2 2025, and $71,000 during Q1 2025.